Other languages Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
9.17 ^USD	-1.50%		-5.17%	-46.22%

05-14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
05-14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	05-14
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	05-07
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	04-15
Neumora's early-stage schizophrenia drug study put on hold	04-15
U.S. FDA places clinical hold on Neumora's schizophrenia drug study	04-15
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	04-15
Neumora Therapeutics Q4 Loss Narrows	03-07
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07
Neumora Therapeutics, Inc. Reported Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-07
Neumora Therapeutics Names Kaya Pai Panandiker as Chief Commercial Officer	01-22
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer	01-22
Neumora Therapeutics, Inc. Appoints Jason Duncan as Chief Legal Officer	12-12
Neumora Therapeutics Starts Phase 1 Trial of NMRA-266 as Potential Treatment of Schizophrenia, Neuropsychiatric Disorders	11-27
Neumora Therapeutics, Inc. Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study	11-27
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-01
Neumora Therapeutics Insider Bought Shares Worth $1,127,064, According to a Recent SEC Filing	23-09-26
Neumora Therapeutics Insider Bought Shares Worth $25,500,000, According to a Recent SEC Filing	23-09-20
Marketing firm Klaviyo lifts IPO price range, targets $9 bln valuation	23-09-18
Neumora Therapeutics, Inc. has completed an IPO in the amount of $250.07 million.	23-09-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Other languages

Filters